Recently Added Drugs
1. Alyftrek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50453 | VERTEX PHARMS INC | NA |
May, 2027
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2029 |
Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient
NCE-1 date: 20 December, 2028
Market Authorisation Date: 20 December, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
ALYFTREK family patents
2. Annovera patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303518 | MAYNE PHARMA | System for providing birth control |
Jun, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: NA
Dosage: RING
More Information on Dosage
ANNOVERA family patents
3. Arynta patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11576878 | AZURITY | Oral solutions comprising lisdexamfetamine salts |
Aug, 2040
(15 years from now) | |
Drugs and Companies using LISDEXAMFETAMINE DIMESYLATE ingredient
Market Authorisation Date: 16 June, 2025
Treatment: NA
Dosage: SOLUTION
More Information on Dosage
ARYNTA family patents
4. Augtyro patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12310968 | BRISTOL | Chiral diaryl macrocycles and uses thereof |
Jul, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 15, 2028 |
| ODE*(ODE*) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-455) | Nov 15, 2030 |
| Orphan Drug Exclusivity(ODE-483) | Jun 13, 2031 |
| Orphan Drug Exclusivity(ODE-488) | Jun 13, 2031 |
Drugs and Companies using REPOTRECTINIB ingredient
NCE-1 date: 16 November, 2027
Market Authorisation Date: 15 November, 2023
Treatment: Treatment of adult patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)
Dosage: CAPSULE
More Information on Dosage
AUGTYRO family patents
5. Avmapki Fakzynja Co-pack (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7897792 | VERASTEM INC | Coumarin derivative having antitumor activity |
Feb, 2027
(1 year, 6 months from now) | |
| US8247411 | VERASTEM INC | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
Apr, 2028
(2 years from now) | |
| US7928109 | VERASTEM INC | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
Aug, 2029
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11400090 | VERASTEM INC | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder |
Oct, 2038
(13 years from now) | |
| US11517573 | VERASTEM INC | Therapeutic compositions, combinations, and methods of use |
Sep, 2040
(15 years from now) | |
| US11873296 | VERASTEM INC | Solid forms of a dual RAF/MEK inhibitor |
Dec, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 08, 2030 |
Drugs and Companies using AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE ingredient
NCE-1 date: 08 May, 2029
Market Authorisation Date: 08 May, 2025
Treatment: Treatment of adult patients with kras-mutated recurrent low-grade serous ovarian cancer (lgsoc) who have received prior systemic therapy, in combination with defactinib; Treatment of adult patients wi...
Dosage: CAPSULE, TABLET
More Information on Dosage
AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) family patents
6. Barhemsys patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329740 | ACACIA | Rescue treatment of post operative nausea and vomiting |
Feb, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2025 |
Drugs and Companies using AMISULPRIDE ingredient
NCE-1 date: 27 February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Prevention and treatment of post-operative nausea and vomiting
Dosage: SOLUTION
More Information on Dosage
BARHEMSYS family patents
7. Brukinsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US10927117 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11851437 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570139 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11142528 | BEONE MEDICINES USA | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11591340 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11884674 | BEONE MEDICINES USA | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11970500 | BEONE MEDICINES USA | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(12 years from now) | |
| US11701357 | BEONE MEDICINES USA | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(13 years from now) | |
| US12233069 | BEONE MEDICINES USA | Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor |
Jun, 2040
(14 years from now) | |
| US11786531 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11896596 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11911386 | BEONE MEDICINES USA | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| ODE*(ODE*) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
Market Authorisation Date: 10 June, 2025
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (s...
Dosage: TABLET
More Information on Dosage
BRUKINSA family patents
8. Crexont patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303481 | IMPAX | Levodopa dosing regimen |
Dec, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 07 August, 2024
Treatment: Treatment of parkinsonism that may follow manganese intoxication
Dosage: CAPSULE, EXTENDED RELEASE
More Information on Dosage
CREXONT family patents
9. Epsolay patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12350382 | MAYNE PHARMA | NA |
Feb, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 22, 2025 |
Drugs and Companies using BENZOYL PEROXIDE ingredient
Market Authorisation Date: 22 April, 2022
Treatment: NA
Dosage: CREAM
More Information on Dosage
EPSOLAY family patents
10. Erleada patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303493 | JANSSEN BIOTECH | Anticancer compositions |
Dec, 2035
(10 years from now) | |
| US12303497 | JANSSEN BIOTECH | Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer |
Jan, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-808) | Sep 17, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 14, 2023 |
Drugs and Companies using APALUTAMIDE ingredient
NCE-1 date: 14 February, 2022
Market Authorisation Date: 14 February, 2018
Treatment: Improvement of overall survival and progression free survival in metastatic, castration-resistant prostate cancer (mcrpc) patients by treatment with 240 mg oral apalutamide in combination with androge...
Dosage: TABLET
How can I launch a generic of ERLEADA before it's drug patent expiration?
More Information on Dosage
ERLEADA family patents
11. Gomekli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12324791 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 11, 2030 |
| Orphan Drug Exclusivity(ODE-488) | Feb 11, 2032 |
Drugs and Companies using MIRDAMETINIB ingredient
NCE-1 date: 11 February, 2029
Market Authorisation Date: 11 February, 2025
Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection
Dosage: CAPSULE
More Information on Dosage
GOMEKLI family patents
12. Ibtrozi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9187489 | NUVATION | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors |
Jun, 2033
(7 years from now) | |
| US9751887 | NUVATION | Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors |
Jun, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 11, 2030 |
Drugs and Companies using TALETRECTINIB ADIPATE ingredient
NCE-1 date: 11 June, 2029
Market Authorisation Date: 11 June, 2025
Treatment: Treatment of patients with locally advanced or metastatic ros1-positive non-small cell lung cancer (nsclc)
Dosage: CAPSULE
More Information on Dosage
IBTROZI family patents
13. Kalydeco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8354427 (Pediatric) | VERTEX PHARMS | Modulators of ATP-binding cassette transporters |
Jan, 2027
(1 year, 5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Pediatric Exclusivity(PED) | Jun 21, 2028 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 22 June, 2027
Market Authorisation Date: 20 May, 2019
Treatment: NA
Dosage: TABLET
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
14. Kalydeco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8354427 (Pediatric) | VERTEX PHARMS INC | Modulators of ATP-binding cassette transporters |
Jan, 2027
(1 year, 5 months from now) | |
|
US10272046 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(8 years from now) | |
|
US11147770 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(8 years from now) | |
|
US11752106 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(8 years from now) | |
|
US12214083 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(8 years from now) | |
|
US8883206 (Pediatric) | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2017 |
| New Indication(I-740) | Feb 21, 2017 |
| New Indication(I-705) | Dec 30, 2017 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-20) | Jan 31, 2019 |
| New Patient Population(NPP) | May 03, 2026 |
| Orphan Drug Exclusivity(ODE-186) | Feb 21, 2021 |
| Orphan Drug Exclusivity(ODE-187) | Dec 29, 2021 |
| Orphan Drug Exclusivity(ODE-188) | Mar 17, 2022 |
| Orphan Drug Exclusivity(ODE-190) | May 17, 2024 |
| Orphan Drug Exclusivity(ODE-189) | Jul 31, 2024 |
| Orphan Drug Exclusivity(ODE-199) | Aug 15, 2025 |
| Orphan Drug Exclusivity(ODE-236) | Apr 29, 2026 |
| Pediatric Exclusivity(PED) | Jun 21, 2028 |
| Orphan Drug Exclusivity(ODE-338) | Dec 21, 2027 |
| Orphan Drug Exclusivity(ODE-435) | May 03, 2030 |
Drugs and Companies using IVACAFTOR ingredient
NCE-1 date: 03 November, 2025
Market Authorisation Date: 03 May, 2023
Treatment: NA
Dosage: GRANULE
How can I launch a generic of KALYDECO before it's drug patent expiration?
More Information on Dosage
KALYDECO family patents
15. Katerzia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336984 | AZURITY | Amlodipine formulations |
Oct, 2037
(12 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: A method of treating hypertension
Dosage: SUSPENSION
How can I launch a generic of KATERZIA before it's drug patent expiration?
More Information on Dosage
KATERZIA family patents
16. Konvomep patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329752 | AZURITY | Compositions and kits for omeprazole suspension |
Jul, 2039
(13 years from now) | |
Drugs and Companies using OMEPRAZOLE; SODIUM BICARBONATE ingredient
Market Authorisation Date: 30 August, 2022
Treatment: NA
Dosage: FOR SUSPENSION
More Information on Dosage
KONVOMEP family patents
17. Koselugo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12318367 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
KOSELUGO family patents
18. Myfembree patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12325714 | SUMITOMO PHARMA | Compositions of thienopyrimidine derivatives |
Sep, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 26, 2024 |
| New Indication(I-898) | Aug 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
| M(M-289) | Jan 27, 2026 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: NA
Dosage: TABLET
More Information on Dosage
MYFEMBREE family patents
19. Neffy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12324838 | ARS PHARMS OPERATION | Intranasal epinephrine formulations and methods for the treatment of disease |
Feb, 2039
(13 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 05 March, 2025
Treatment: NA
Dosage: SPRAY
More Information on Dosage
NEFFY family patents
20. Nubeqa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12329742 | BAYER HEALTHCARE | Pharmaceutical composition of darolutamide |
May, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 30, 2024 |
| New Indication(I-900) | Aug 05, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: 31 July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
NUBEQA family patents
21. Orgovyx patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12325714 | SUMITOMO PHARMA | Compositions of thienopyrimidine derivatives |
Sep, 2033
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336990 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer
Dosage: TABLET
More Information on Dosage
ORGOVYX family patents
22. Ponvory patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12336980 | VANDA PHARMS INC | Dosing regimen for a selective S1P1 receptor agonist |
Dec, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 18, 2026 |
Drugs and Companies using PONESIMOD ingredient
NCE-1 date: 18 March, 2025
Market Authorisation Date: 18 March, 2021
Treatment: Treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults using a dose titratio...
Dosage: TABLET
More Information on Dosage
PONVORY family patents
23. Purified Cortrophin Gel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12324787 | ANI PHARMS | Contactless optical process for identifying objects |
Oct, 2043
(18 years from now) | |
Drugs and Companies using CORTICOTROPIN ingredient
Market Authorisation Date: 01 January, 1982
Treatment: NA
Dosage: INJECTABLE
More Information on Dosage
PURIFIED CORTROPHIN GEL family patents
24. Radicava Ors patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12310946 | MITSUBISHI TANABE | Pharmaceutical composition for oral administration of edaravone and method of administering same |
Nov, 2041
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2025 |
| Orphan Drug Exclusivity(ODE-144) | May 12, 2029 |
Drugs and Companies using EDARAVONE ingredient
Market Authorisation Date: 12 May, 2022
Treatment: Treatment of amyotrophic lateral sclerosis by administering a liquid edaravone composition relative to the timing and type of food consumption
Dosage: SUSPENSION
How can I launch a generic of RADICAVA ORS before it's drug patent expiration?
More Information on Dosage
RADICAVA ORS family patents
25. Relistor patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303592 | SALIX PHARMS | Formulations for parenteral delivery of compounds and uses thereof |
Aug, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 24, 2013 |
| New Product(NP) | Jul 19, 2019 |
Drugs and Companies using METHYLNALTREXONE BROMIDE ingredient
NCE-1 date: 24 April, 2012
Market Authorisation Date: 27 September, 2010
Treatment: Treatment of opioid-induced constipation (oic) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., ...
Dosage: SOLUTION
How can I launch a generic of RELISTOR before it's drug patent expiration?
More Information on Dosage
RELISTOR family patents
26. Ryaltris patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12303635 | GLENMARK SPECLT | Dispensing device and pharmaceutical composition for the treatment of rhinitis |
Apr, 2039
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 13, 2025 |
Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 January, 2022
Treatment: NA
Dosage: SPRAY, METERED
More Information on Dosage
RYALTRIS family patents
27. Symdeko (copackaged) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50453 | VERTEX PHARMS INC | NA |
May, 2027
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 12, 2023 |
| Orphan Drug Exclusivity(ODE-173) | Feb 12, 2025 |
| Orphan Drug Exclusivity(ODE-247) | Jun 21, 2026 |
| Orphan Drug Exclusivity(ODE-335) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 12 February, 2022
Market Authorisation Date: 21 June, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
SYMDEKO (COPACKAGED) family patents
28. Tarpeyo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12311057 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2024 |
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression, by release of budesonide from the formulation
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TARPEYO family patents
29. Tryptyr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10028920 | ALCON LABS INC | Methods for treating occular irritation involving tearing by administering modulators of TRPM8 |
Sep, 2031
(6 years from now) | |
| US9095609 | ALCON LABS INC | Ophthalmic composition comprising ws-12 and methods to treat xerophthalmia |
Sep, 2031
(6 years from now) | |
| US9433679 | ALCON LABS INC | Use of TRMP8 for treating opthalmic diseases or conditions involving tearing |
Sep, 2031
(6 years from now) | |
| US11850221 | ALCON LABS INC | Ophthalmic pharmaceutical compositions and uses thereof |
Dec, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2030 |
Drugs and Companies using ACOLTREMON ingredient
NCE-1 date: 28 May, 2029
Market Authorisation Date: 28 May, 2025
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS
More Information on Dosage
TRYPTYR family patents
30. Tryvio patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12297189 | IDORSIA | Crystalline forms of a 4-pyrimidinesulfamide derivative aprocitentan |
Feb, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2029 |
Drugs and Companies using APROCITENTAN ingredient
NCE-1 date: 22 March, 2028
Market Authorisation Date: 19 March, 2024
Treatment: NA
Dosage: TABLET
More Information on Dosage
TRYVIO family patents
31. Ubrelvy patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12310953 | ABBVIE | Pharmaceutical formulations for the treatment of migraine |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2024 |
Drugs and Companies using UBROGEPANT ingredient
NCE-1 date: 24 December, 2023
Market Authorisation Date: 23 December, 2019
Treatment: NA
Dosage: TABLET
More Information on Dosage
UBRELVY family patents
32. Valtoco patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12337061 | NEURELIS INC | Administration of benzodiazepine compositions |
Jun, 2032
(6 years from now) | |
| US12324852 | NEURELIS INC | Administration of benzodiazepine compositions |
Oct, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 10, 2023 |
| Orphan Drug Exclusivity(ODE-279) | Jan 10, 2027 |
| New Patient Population(NPP) | Apr 15, 2028 |
Drugs and Companies using DIAZEPAM ingredient
Market Authorisation Date: 10 January, 2020
Treatment: Nasal administration of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient's usual seizure pattern in patients with ep...
Dosage: SPRAY
More Information on Dosage
VALTOCO family patents
33. Vasostrict patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12186362 | ENDO OPERATIONS | Vasopressin formulations for use in treatment of hypotension |
Jan, 2035
(9 years from now) | |
Drugs and Companies using VASOPRESSIN ingredient
Market Authorisation Date: 17 April, 2014
Treatment: NA
Dosage: SOLUTION
How can I launch a generic of VASOSTRICT before it's drug patent expiration?
More Information on Dosage
VASOSTRICT family patents
34. Vykat Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12343348 | SOLENO THERAP | Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome |
Nov, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 26, 2028 |
Drugs and Companies using DIAZOXIDE CHOLINE ingredient
Market Authorisation Date: 26 March, 2025
Treatment: Treating hyperphagia and reducing hyperphagic aggressive behaviors in prader-willi syndrome patients
Dosage: TABLET, EXTENDED RELEASE
More Information on Dosage
VYKAT XR family patents
35. Widaplik patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10322117 | GEORGE MEDICINES | Compositions for the treatment of hypertension |
Jan, 2038
(12 years from now) | |
| US10799487 | GEORGE MEDICINES | Compositions for the treatment of hypertension |
Jan, 2038
(12 years from now) | |
Drugs and Companies using AMLODIPINE BESYLATE; INDAPAMIDE; TELMISARTAN ingredient
Market Authorisation Date: 05 June, 2025
Treatment: A method of treating hypertension
Dosage: TABLET
More Information on Dosage
WIDAPLIK family patents
36. Xaciato patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12303563 | ORGANON LLC | Topical formulations and treatments |
Sep, 2036
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 07, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Dec 07, 2029 |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 07 December, 2021
Treatment: NA
Dosage: GEL
More Information on Dosage
XACIATO family patents
37. Xofluza patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8987441 | GENENTECH INC | Substituted polycyclic carbamoyl pyridone derivative prodrug |
Sep, 2031
(6 years from now) | |
| US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| US10759814 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815835 | GENENTECH INC | Substituted polycyclic carbamolypyridone derivative |
Jun, 2030
(4 years from now) | |
| US8927710 | GENENTECH INC | Substituted polycyclic carbamoylpyridone derivative |
May, 2031
(5 years from now) | |
| US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(10 years from now) | |
| US11306106 | GENENTECH INC | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
Aug, 2037
(12 years from now) | |
| US11261198 | GENENTECH INC | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
Sep, 2038
(13 years from now) | |
| US11925648 | GENENTECH INC | Solid dosage form having excellent stability |
Apr, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-811) | Oct 16, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 24, 2023 |
| M(M-187) | Dec 19, 2027 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: 24 October, 2022
Market Authorisation Date: 23 November, 2020
Treatment: Method for treating influenza; Method for post-exposure prophylaxis of influenza
Dosage: FOR SUSPENSION
How can I launch a generic of XOFLUZA before it's drug patent expiration?
More Information on Dosage
XOFLUZA family patents
38. Yutrepia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10898494 | LIQUIDIA TECH | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | |
| US11660304 | LIQUIDIA TECH | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | |
| US11712442 | LIQUIDIA TECH | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | |
| US11744835 | LIQUIDIA TECH | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | |
| US11744836 | LIQUIDIA TECH | Dry powder treprostinil for the treatment of pulmonary hypertension |
May, 2037
(11 years from now) | |
Drugs and Companies using TREPROSTINIL SODIUM ingredient
Market Authorisation Date: 23 May, 2025
Treatment: Method of treating pulmonary arterial hypertension or pulmonary hypertension associated with interstitial disease by administering treprostinil or a salt thereof by using an inhalation device; Definit...
Dosage: POWDER
More Information on Dosage
YUTREPIA family patents
39. Zepzelca patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12324806 | JAZZ | Method of treating SCLC and managing hepatotoxicity |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 15, 2025 |
| Orphan Drug Exclusivity(ODE-304) | Jun 15, 2027 |
Drugs and Companies using LURBINECTEDIN ingredient
NCE-1 date: 15 June, 2024
Market Authorisation Date: 15 June, 2020
Treatment: Treating metastatic sclc after platinum chemotherapy with lurbinectedin monotherapy by reducing the dose for grade ≥3 hepatotoxicity from 3.2 to 2.6 mg/m2 and 2.6 to 2.0 mg/m2 lurbinectedin within 35 ...
Dosage: POWDER
More Information on Dosage
ZEPZELCA family patents
40. Zoryve patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12310956 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half-life |
Jun, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2026 |
| New Patient Population(NPP) | Oct 05, 2026 |
| New Strength(NS) | Jul 09, 2027 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 09 July, 2024
Treatment: Topical treatment of plaque psoriasis of the scalp and body in patients 12 years of age and older
Dosage: FOAM; CREAM
More Information on Dosage
ZORYVE family patents